BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas - Nyman, H; Jerkeman, M; Karjalainen-Lindsberg, M; Banham, A; Enblad, G; Leppa, S (2008)